Fig. 5: TPM2 is a prognostic biomarker in pediatric EBV-negative BL. | Leukemia

Fig. 5: TPM2 is a prognostic biomarker in pediatric EBV-negative BL.

From: Single-cell transcriptomics of pediatric Burkitt lymphoma reveals intra-tumor heterogeneity and markers of therapy resistance

Fig. 5

A Box and Whisker plot displaying TPM2 expression fold change in diagnostic specimens of 21 non-responder (NR) and 36 responder (R) patients, as detected by qRT-PCR. (*p < 0.05 by Mann-Whitney U Test). B Kaplan-Meier plot for progression free survival (PFS) analysis in the BL patients (n = 57) stratified based on expression of TPM2 transcript, as detected by qRT-PCR in (A). “TPM2 low” and “TPM2 high” are patients with TPM2 expression below and above the median expression in the dataset, respectively. C Kaplan-Meier plot for PFS analysis in the subset of patients (n = 35) carrying mutated TP53 and stratified based on expression of TPM2 transcript, as detected by qRT-PCR in (A). D Bar plot displaying the percentage of cases which scored as positive (TPM2-pos) or negative (TPM2-neg) for TPM2 protein expression, as detected by IHC analysis in 11 NR and 36 R patients. (Right) Representative images of TPM2 detection by IHC in BL nodal diagnostic biopsies from a R (R37) and a NR (NR19). TPM2 expression is detectable in the tumor cells of the NR and in the normal muscle, stroma, and macrophages of all specimens. E Kaplan-Meier plot for PFS analysis in BL patients (n = 47) stratified based on TPM2 protein expression in the tumor cells.

Back to article page